Will a 7q11.22 duplication be detected by a next-generation sequencing (NGS) test?

Detection of 7q11.22 Duplication by Next-Generation Sequencing

A 7q11.22 duplication can be detected by next-generation sequencing (NGS), but detection depends critically on the specific type of NGS test performed and the bioinformatics pipeline used for copy number variant (CNV) analysis.

Key Factors Determining Detection

Type of NGS Test Matters

The ability to detect this duplication varies significantly by sequencing approach 1:

• Whole Genome Sequencing (WGS): Best option for CNV detection, including 7q11.22 duplications
• Whole Exome Sequencing (WES): Can detect multi-exon CNVs with reasonable sensitivity 1
• Targeted Gene Panels: Limited capability; only detects CNVs if genes within 7q11.22 are specifically included in the panel

Size and Coverage Requirements

The 7q11.23 duplication (note: the question asks about 7q11.22, but the clinically relevant region is 7q11.23) typically spans 1.31-1.42 Mb 2, 3. Research demonstrates that:

• Panel-based NGS reliably detects CNVs >300 kb on autosomes when adequate exons are covered 4
• The 7q11.23 duplication falls well above this threshold and should be detectable
• Detection accuracy improves with larger variant size 4

Critical Bioinformatics Requirements

Standard NGS variant calling pipelines focus on single nucleotide variants (SNVs) and small insertions/deletions (indels), NOT CNVs 1. Detection requires:

Specialized CNV Analysis Tools

Current best practices recommend using multiple tools for structural variant calling 5. Validated options include:

• ExomeDepth (sensitivity 97-100% for multi-exon deletions/duplications) 6
• CNVkit 4
• XHMM 7

Important Caveats

1. Not all clinical NGS tests include CNV analysis - Many laboratories only report SNVs and indels unless CNV calling is specifically requested or part of their standard pipeline 8

2. Validation is essential - Clinical laboratories should validate their CNV detection pipeline using:

   • Standard truth sets (GIAB, SEQC2) 5
   • Real patient samples with known CNVs 5
   • Confirmation by chromosomal microarray analysis (CMA) or FISH 4, 9, 2

3. Read depth matters - Adequate sequencing coverage is critical for CNV detection 6. Panels typically achieve 500-1000×, exomes 100-150×, and genomes 30-60× coverage 1

Clinical Recommendations

When Ordering NGS Testing

Explicitly confirm with the laboratory whether their NGS test includes CNV analysis - this is not automatically included in all NGS reports. Recent evidence shows NGS with CNV analysis can successfully identify 7q11.23 duplications prenatally and postnatally 9, 2, 3.

If 7q11.23 Duplication is Suspected

Consider ordering:

1. Chromosomal microarray analysis (CMA) - remains the gold standard for CNV detection
2. NGS with validated CNV calling - if the laboratory has validated their pipeline for CNV detection
3. FISH - for targeted confirmation if duplication is identified

Phenotypic Considerations

The 7q11.23 duplication syndrome shows significant phenotypic heterogeneity 2, 3:

• Prenatal: 50% show ultrasound anomalies (cleft palate, ventriculomegaly) 2
• Postnatal: intellectual disability, language delay, attention deficit hyperactivity disorder 3
• 42.9-50% are inherited from phenotypically normal or mildly affected parents 2, 10

This inheritance pattern means parental testing is crucial for genetic counseling, as apparently unaffected parents may carry the duplication or even have reciprocal deletion/duplication arrangements 10.

Bottom Line

NGS CAN detect 7q11.22/7q11.23 duplications, but only if the test includes CNV analysis using validated bioinformatics tools 4, 8, 6, 9, 2. Always verify this capability with your laboratory before relying on NGS alone for CNV detection. When clinical suspicion is high, CMA remains the most reliable first-line test.